List of Excipients in Branded Drug RYALTRIS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HIKMA SPECIALTY USA INC	RYALTRIS	olopatadine hydrochloride and mometasone furoate	59467-700	BENZALKONIUM CHLORIDE	2039-04-08
HIKMA SPECIALTY USA INC	RYALTRIS	olopatadine hydrochloride and mometasone furoate	59467-700	CARBOXYMETHYLCELLULOSE SODIUM	2039-04-08
HIKMA SPECIALTY USA INC	RYALTRIS	olopatadine hydrochloride and mometasone furoate	59467-700	CELLULOSE, MICROCRYSTALLINE	2039-04-08

RYALTRIS Excipient Strategy, Formulation IP, and Commercial Opportunities

Last updated: August 10, 2026

RYALTRIS is a once-daily, fixed-dose intranasal suspension containing olopatadine hydrochloride and mometasone furoate. Its principal excipient opportunity is not a simple substitution of inactive ingredients. The commercial value lies in preserving dose uniformity, spray performance, suspension stability, microbiological quality, and patient tolerability while creating differentiated preservative-free, device-enabled, or region-specific presentations.

The U.S. product delivers 665 mcg of olopatadine hydrochloride, equivalent to 600 mcg of olopatadine, and 25 mcg of mometasone furoate per spray. The approved formulation uses carboxymethylcellulose sodium, dibasic sodium phosphate, polysorbate 80, benzalkonium chloride, disodium edetate, sodium chloride, hydrochloric acid, sodium hydroxide, and purified water [1].

What is RYALTRIS and how is it regulated?

RYALTRIS is a prescription nasal spray approved by the U.S. Food and Drug Administration in 2021 for the treatment of seasonal allergic rhinitis in patients aged 12 years and older whose symptoms are inadequately controlled with either an intranasal antihistamine or corticosteroid alone [2].

Attribute	RYALTRIS detail
Active ingredients	Olopatadine hydrochloride and mometasone furoate
U.S. strength	665 mcg olopatadine hydrochloride and 25 mcg mometasone furoate per spray
Dosage form	Metered-dose nasal spray, suspension
U.S. administration	Two sprays in each nostril once daily
U.S. sponsor	Glenmark Pharmaceuticals Ltd.
U.S. NDA	214697
FDA approval	2021
Primary indication	Seasonal allergic rhinitis
Commercial class	Fixed-dose intranasal antihistamine-corticosteroid combination
Biosimilar pathway	Not applicable
Generic pathway	Abbreviated New Drug Application, or ANDA, under section 505(j)

The product combines local H1-antihistamine activity from olopatadine with anti-inflammatory corticosteroid activity from mometasone. The combination competes with separate-component therapy and other intranasal combinations such as DYMISTA, which contains azelastine hydrochloride and fluticasone propionate.

What excipients are used in RYALTRIS?

The U.S. RYALTRIS formulation contains the following inactive ingredients:

Excipient	Likely technical function
Carboxymethylcellulose sodium	Suspending and viscosity-modifying agent
Dibasic sodium phosphate	Buffering component
Polysorbate 80	Wetting and dispersion aid
Benzalkonium chloride	Preservative
Disodium edetate	Chelating agent and preservative-support excipient
Sodium chloride	Tonicity adjustment
Hydrochloric acid	pH adjustment
Sodium hydroxide	pH adjustment
Water	Vehicle

The formulation is a suspension rather than a clear solution. That distinction drives the technical risk. The active particles must remain adequately dispersed during storage, resuspend after shaking, and deliver a consistent amount through the metered pump across the labeled life of the product.

The excipients must also support a nasal product that is acceptable for repeated use. Viscosity, spray force, plume geometry, droplet-size distribution, nozzle deposition, and local irritation can affect adherence and commercial differentiation.

How does RYALTRIS use excipients to control suspension performance?

Carboxymethylcellulose sodium is central to the formulation strategy. It can increase continuous-phase viscosity, slow sedimentation, and improve suspension uniformity. Excessive viscosity, however, can increase actuation force, impair plume formation, or reduce dose delivery through the pump.

Polysorbate 80 supports wetting of hydrophobic drug particles and can reduce aggregation. Its concentration must be controlled because surfactant levels can affect foam formation, extractables, chemical stability, and nasal tolerability.

Disodium edetate can bind trace metals that catalyze degradation pathways. It may also support preservative performance. The formulation therefore uses a multi-excipient control system rather than relying on one stabilizer.

Sodium chloride controls tonicity. The phosphate system and pH adjustment agents establish the formulation environment required for drug stability and patient acceptability. Benzalkonium chloride provides antimicrobial preservation but creates a recognized lifecycle opportunity because repeated exposure to benzalkonium-containing nasal products has generated concern about mucosal irritation and epithelial effects in some patients [3].

Which critical quality attributes matter most?

The highest-value formulation controls are:

1. Delivered dose uniformity across the bottle.
2. Particle-size distribution for both active ingredients.
3. Redispersibility after storage.
4. Spray pattern and plume geometry.
5. Priming and repriming performance.
6. Microbial limits and preservative effectiveness.
7. Viscosity and sedimentation rate.
8. Assay and degradation products.
9. Container-closure compatibility.
10. Local nasal tolerability.

A generic or follow-on product cannot rely on the same qualitative composition alone. It must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements, including appropriate comparative performance for the nasal spray device [4].

What excipient strategies could improve RYALTRIS?

Preservative-free RYALTRIS

The clearest commercial opportunity is a preservative-free presentation using a multidose device with validated microbial protection. Potential platforms include:

• One-way valve systems.
• Sterile manufacturing and aseptic filling.
• Unit-dose or bidose packaging.
• Barrier systems that limit microbial ingress.
• Device architectures that isolate the formulation from ambient air.

A preservative-free version could target patients who experience nasal irritation or who use intranasal therapy chronically. The trade-off is higher device cost, more complex filling operations, and potentially greater regulatory burden.

A preservative-free formulation would need to preserve the current suspension attributes. Removing benzalkonium chloride may change microbial risk, adsorption behavior, wetting, and chemical stability. The device, not only the liquid formulation, would become part of the preservative strategy.

Alternative viscosity systems

Carboxymethylcellulose sodium is effective but not the only possible suspending polymer. Development programs could evaluate:

• Microcrystalline cellulose and carboxymethylcellulose combinations.
• Hydroxypropyl methylcellulose.
• Polyvinyl alcohol.
• Xanthan gum at low concentrations.
• Other pharmaceutically accepted cellulose derivatives.

The commercial objective would be a better balance between suspension stability and sprayability. A polymer change that lowers actuation force or improves dose uniformity could support a device or formulation patent, provided the claims are technically distinct and non-obvious.

Lower-irritation preservative systems

Possible approaches include reducing benzalkonium chloride concentration, using a different preservative system, or combining a lower preservative level with improved device protection. Candidate systems must be evaluated for:

• Antimicrobial effectiveness.
• Nasal epithelial compatibility.
• Active-ingredient stability.
• Pump compatibility.
• Extractables and leachables.
• Regional regulatory acceptability.

The replacement of benzalkonium chloride is not automatically advantageous. A new preservative may introduce its own irritation, toxicity, or compatibility issues.

Improved particle engineering

Olopatadine and mometasone have different physicochemical properties. Particle engineering may improve suspension uniformity and reduce settling. Relevant approaches include:

• Narrower particle-size distributions.
• Controlled crystallinity.
• Surface treatment or wetting optimization.
• Spray-dried or engineered particles.
• Separate particle populations optimized for each active ingredient.

Particle engineering has high commercial value because it can improve dose reproducibility without changing the nominal strength. It can also create manufacturing know-how that is difficult for competitors to replicate.

What formulation patents could protect RYALTRIS improvements?

The most defensible formulation IP would generally protect technical performance rather than a broad list of conventional excipients. Potential claim categories include:

IP category	Potential protected subject matter
Composition	Defined ranges of polymer, surfactant, buffer, preservative, and tonicity agent
Suspension	Particle-size distribution, sedimentation profile, redispersibility, or viscosity window
Device	Metered pump, valve, actuator, nozzle, or preservative-free container
Manufacturing	Milling, homogenization, mixing order, filling, or sterilization process
Use	Treatment of allergic rhinitis with specified dosing or patient populations
Performance	Dose uniformity, plume geometry, spray pattern, or storage stability

Broad claims covering olopatadine plus mometasone are likely to face prior-art scrutiny because the active-ingredient combination and intranasal delivery concept are commercially established. Narrower claims directed to a defined excipient range, particle architecture, device configuration, or manufacturing process may provide stronger practical protection.

The FDA Orange Book remains the controlling source for listed patents and regulatory exclusivity associated with the U.S. NDA. FDA approval does not itself establish patent scope. A current patent review should distinguish listed patents from unlisted formulation know-how, pending applications, foreign rights, and trade secrets [5].

When does RYALTRIS lose exclusivity?

RYALTRIS does not have biologic exclusivity because it is a small-molecule drug. The relevant competitive pathway is an ANDA, not a biosimilar application.

Exclusivity issue	RYALTRIS relevance
New chemical entity exclusivity	Not applicable to the fixed-dose combination in the same way as a novel active ingredient
Three-year clinical investigation exclusivity	Potentially relevant if the approval relied on qualifying new clinical investigations
Pediatric exclusivity	Applies only if separately granted
Orphan exclusivity	Not applicable to seasonal allergic rhinitis
Patent exclusivity	Depends on issued and listed patents, expiration dates, and any patent-term adjustment
ANDA entry	Possible after applicable regulatory and patent barriers expire or are successfully challenged

No reliable commercial conclusion should be drawn from the approval date alone. Generic entry depends on the Orange Book patent record, the timing of ANDA filings, Paragraph IV certifications, litigation, settlements, and any applicable regulatory exclusivity.

What Paragraph IV challenges and generic entry risks exist?

A generic applicant could challenge relevant RYALTRIS patents through a Paragraph IV certification. The principal attack points would likely include:

• Obviousness of combining olopatadine and mometasone.
• Conventionality of the excipient system.
• Lack of unexpected results across claimed concentration ranges.
• Obviousness of suspension or particle-size limitations.
• Inadequate written description or enablement.
• Non-infringement based on a different preservative, polymer, device, or manufacturing process.

The principal defenses would focus on unexpected dose uniformity, stability, tolerability, device interaction, or clinical performance produced by the claimed formulation.

A generic launch could occur through several scenarios:

Launch scenario	Commercial effect
Patent expiry with no litigation	Earliest conventional generic competition
Paragraph IV challenge followed by settlement	Entry date depends on settlement terms
Litigation with 30-month stay	Delayed launch while infringement litigation proceeds
Non-infringing formulation	Potential earlier entry if regulatory requirements are satisfied
Authorized generic	Price pressure without an independent ANDA entrant
Device-related delay	ANDA approval may occur before commercial launch if device supply is constrained

For RYALTRIS, device and formulation equivalence are likely to be more important than for a conventional oral tablet. The generic must reproduce the delivered dose and nasal spray performance, not merely match the active ingredients.

How strong is the RYALTRIS patent estate?

The commercial strength of the estate depends on claim breadth, remaining patent term, Orange Book listing status, and the extent to which competitors can design around the formulation.

A strong estate would contain multiple layers:

1. Active-ingredient combination claims.
2. Narrow formulation claims.
3. Particle-size or suspension-performance claims.
4. Device and container-closure claims.
5. Manufacturing-process claims.
6. Method-of-use claims.
7. Foreign counterparts in major pharmaceutical markets.

Method-of-use patents may have less practical blocking value where generic applicants can pursue skinny labeling or omit protected indications. Formulation and device patents are usually more relevant to a fixed-dose nasal suspension because they can constrain the product configuration submitted for approval.

The weakest point would be reliance on conventional excipients without a demonstrated technical effect. The strongest point would be a reproducible relationship between a defined excipient or particle parameter and an unexpected improvement in delivered dose, storage stability, spray performance, or tolerability.

What is the FDA status and Orange Book position of RYALTRIS?

RYALTRIS is FDA-approved under NDA 214697 for seasonal allergic rhinitis in patients 12 years and older [2]. It is a prescription product and is marketed as a metered-dose nasal spray.

The Orange Book should be used to evaluate:

• Patent numbers listed against NDA 214697.
• Patent-use codes.
• Patent expiration dates.
• Regulatory exclusivity codes.
• Any changes to listed patents.
• Whether an ANDA applicant has submitted a Paragraph IV certification.

The FDA label identifies the approved formulation and administration instructions but does not provide a complete freedom-to-operate analysis. Patent protection may also exist outside the Orange Book through manufacturing, device, process, or foreign rights.

Which companies compete with RYALTRIS?

RYALTRIS competes in a crowded intranasal allergy market.

Product	Active ingredients	Strategic comparison
RYALTRIS	Olopatadine plus mometasone	Fixed-dose antihistamine-corticosteroid combination
DYMISTA	Azelastine plus fluticasone propionate	Established combination competitor
PATANASE	Olopatadine	Antihistamine comparator
NASONEX	Mometasone furoate	Corticosteroid comparator
Flonase products	Fluticasone formulations	Broad OTC and prescription competition
Astepro products	Azelastine	OTC and prescription antihistamine competition

The principal commercial challenge is the availability of generic and over-the-counter intranasal therapies. RYALTRIS must justify its price through convenience, symptom control, tolerability, adherence, and payer positioning.

What licensing and manufacturing opportunities exist?

The product offers several partnering opportunities:

• Regional licensing outside the originator’s core markets.
• Contract manufacturing of suspension bulk and finished nasal spray.
• Device licensing for preservative-free delivery.
• Excipient supplier partnerships for specialty cellulose systems.
• Particle-engineering collaborations.
• Authorized-generic arrangements.
• Co-development of pediatric or lower-dose presentations.
• Private-label supply for markets where combination nasal products are accepted.

Manufacturing barriers are meaningful. A capable partner needs expertise in micronized active ingredients, suspension homogeneity, high-precision filling, metered nasal pumps, microbial control, and stability testing. The formulation may be technically reproducible but commercially difficult to scale without robust process controls.

The most attractive supplier opportunity is a differentiated excipient or device platform that can be incorporated without changing the active strength. The supplier must demonstrate consistent pharmaceutical grade, low extractables, global regulatory support, and reliable supply.

What revenue exposure and commercial opportunities does RYALTRIS have?

Product-specific revenue is not always separately disclosed by the sponsor, limiting precise exposure estimates. The commercial opportunity is concentrated in seasonal allergic rhinitis, where patients often use therapy repeatedly during high-pollen periods and may value rapid symptom relief.

Potential revenue expansion routes include:

• Preservative-free multidose delivery.
• Pediatric labeling expansion.
• Lower-cost regional presentations.
• Improved actuator ergonomics.
• Combination packs or adherence packaging.
• OTC transition, if supported by regulatory evidence.
• Expansion into perennial allergic rhinitis or related nasal indications.
• Licensing in markets with limited access to fixed-dose combinations.
• Authorized generic supply after loss of exclusivity.

Excipient-led differentiation is most valuable when it produces a measurable patient or payer benefit. A formulation that merely replaces one conventional excipient with another is unlikely to sustain premium pricing.

Key Takeaways

• RYALTRIS is a fixed-dose nasal suspension containing olopatadine hydrochloride and mometasone furoate.
• Its key excipients are carboxymethylcellulose sodium, polysorbate 80, phosphate buffer, benzalkonium chloride, disodium edetate, sodium chloride, pH adjusters, and water.
• The highest-value technical issues are suspension stability, dose uniformity, spray performance, preservative effectiveness, and nasal tolerability.
• A preservative-free device and lower-irritation preservative strategy are the clearest lifecycle opportunities.
• Particle engineering, polymer optimization, and device integration could support differentiated formulation IP.
• Generic competition will proceed through the ANDA pathway, with Paragraph IV challenges possible against applicable listed patents.
• Biosimilar risk does not apply because RYALTRIS is a small-molecule product.
• Commercial value is more likely to arise from device, formulation, and manufacturing differentiation than from conventional excipient substitution.
• The current Orange Book record and patent family should be reviewed for definitive expiration dates, patent-use codes, and litigation exposure.

FAQs

Can RYALTRIS be reformulated without benzalkonium chloride?

Yes. A preservative-free or reduced-benzalkonium formulation is technically possible, but it would require a new microbial-control strategy and comparative stability, device, and spray-performance data.

Which excipient is most important for RYALTRIS suspension stability?

Carboxymethylcellulose sodium is likely the principal suspending and viscosity-modifying excipient. Its concentration must balance sedimentation control against sprayability and actuation force.

Is a preservative-free RYALTRIS likely to support new patent claims?

Potentially. Patentability would depend on the specific device, formulation, microbial-control mechanism, and demonstrated technical effect. A generic preservative-free claim without a distinctive technical feature would face prior-art risk.

Can a generic use different excipients from RYALTRIS?

Yes, if the generic product satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, device performance, and labeling. A different excipient system may help avoid formulation claims but can create new equivalence and stability challenges.

Does RYALTRIS have biosimilar competition?

No. RYALTRIS is not a biologic. Competitive entry would occur through an ANDA, an authorized generic, or a follow-on product governed by small-molecule drug regulations.

References

1. DailyMed. (2024). RYALTRIS: Olopatadine hydrochloride and mometasone furoate nasal spray, suspension, prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2021). RYALTRIS approval package, NDA 214697. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2017). Drug products containing benzalkonium chloride: Safety and labeling considerations. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for nasal aerosols and nasal sprays for local action. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.